Intra-Cellular Therapies, Inc.(NASDAQ: ITCI) today announced the pricing of its previously announced underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $29.50 per share. All of the shares in the offering will be sold by Intra-Cellular Therapies, with gross proceeds to Intra-Cellular Therapies expected to be $295 million from the offering of an aggregate of 10,000,000 shares before deducting underwriting discounts and commissions and offering expenses.
Intra-Cellular Therapies has granted the underwriters a30-dayoption to purchase up to an additional 1,500,000 shares on the same terms and conditions. The expected net proceeds to Intra-Cellular Therapies referenced above do not include any net proceeds that Intra-Cellular Therapies would receive if the underwriters exercise such option. The offering is expected to close on January 10, 2020, subject to customary closing conditions.
J.P. Morgan Securities LLC, SVB Leerink LLC and Evercore Group L.L.C. are acting as joint book-running managers for the offering.Cantor Fitzgerald & Co. and Canaccord Genuity LLC are acting as co-lead managers and JMP Securities LLC is acting as co-manager for the offering.